Newsfeeds - Spark Newswire

2 minute read

Looking At AbbVie’s Recent Whale Trades

Today, 4:28 PM

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

ABBV

2 minute read

This Stock ‘Benefits From Volatility,’ Analyst Says On CNBC’s Final Trades, Plus AbbVie And ETF Plays

By Priya Nigam

Today, 4:28 PM

CME Group Inc (NASDAQ: CME) “benefits from volatility.” That's according to Karen Firestone of Aureus Asset Management who appeared on CNBC’s “Halftime Report Final Trades.”

ABBV

1 minute read

Amazon, Honeywell Are CNBC ‘Fast Money’ Calls Of The Day; Steve Weiss Is Shorting This Sector

By AJ Fabino

Today, 4:28 PM

CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors.

ABBV

2 minute read

Peering Into AbbVie’s Recent Short Interest

By Benzinga Insights

Today, 4:28 PM

AbbVie's (NYSE:ABBV) short percent of float has fallen 6.33% since its last report. The company recently reported that it has 13.01 million shares sold short, which is 0.74% of all regular shares that are available for trading.

ABBV

3 minute read

FDA
News

AbbVie Announced FDA Approved the Use of Imbruvica for the Treatment of Pediatric Patients One Year and Older With cGVHD After Failure of One or More Lines of Systemic Therapy

By Charles Gross

Today, 4:28 PM

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

ABBV

2 minute read

Looking At AbbVie’s Recent Whale Trades

By Benzinga Insights

Today, 4:28 PM

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

ABBV

1 minute read

This Analyst Cuts I-Mab’s Price Target By 43%

By Vandana Singh

Today, 4:28 PM

I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents.

ABBV

4 minute read

Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 4:28 PM

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle platform.

1 minute read

AbbVie Calls Off Early-Stage Trial For I-Mab’s CD47-Targeted Blood Cancer Candidate

By Vandana Singh

Today, 4:28 PM

I-Mab (NASDAQ:IMAB) disclosed in an SEC filing that AbbVie Inc (NYSE:ABBV) would discontinue the global Phase 1b study of lemzoparlimab combination therapy with…

ABBV

2 minute read

I-Mab And AbbVie Entered Amendment To Original License And Collaboration Agreement; Parties Will Continue To Collaborate On Anti-CD47 Antibody Program, I-Mab Eligible to Receive Up To $1.295B Milestones

By Bill Haddad

Today, 4:28 PM

I-Mab (the “Company”) (NASDAQ:IMAB) today announced that the Company and AbbVie Global Enterprises Ltd. (as assignee of AbbVie Ireland Unlimited Company) (“AbbVie”) have entered into an amendment

ABBV